{
  "metadata": {
    "case_id": 36,
    "model": "GPT-5.1",
    "timestamp": "2025-11-29T15:55:52.902075",
    "total_alignments": 3,
    "target_section": "protocolSection",
    "ground_truth_path": "/{YOURPATH}/samples/CTG/protocolSection/1_100/36_NCT01590433.json",
    "prediction_path": "/{YOURPATH}/restructured_outputs_protocol/GPT-5.1/36_GPT-5.1.json",
    "shard_range": "1_100"
  },
  "alignments": [
    {
      "field_path": "protocolSection.armsInterventionsModule.armGroups",
      "algorithm": "hungarian",
      "ref_count": 2,
      "pred_count": 2,
      "similarity_matrix": [
        [
          0.74,
          0.5
        ],
        [
          0.45,
          0.82
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.74,
          "status": "matched",
          "ref_item": {
            "label": "Exenatide",
            "type": "EXPERIMENTAL",
            "description": "Subjects will be randomly assigned to the exenatide study treatment group or to the placebo study treatment group. Subjects will have a 33 percent chance of being assigned to the placebo study treatment group and a 66 percent chance of being assigned to exenatide study treatment. Subjects will not be able to choose the study group to which they will be assigned. All study participants will receive individualized dietary counseling based on food logs. Subjects who receive exenatide will not be assigned to follow a reduced-calorie diet in addition to study treatment. Subjects will not know whether they are receiving exenatide or placebo, but the unblinded members of study team will know which they are receiving.",
            "interventionNames": [
              "Drug: Exenatide"
            ]
          },
          "pred_item": {
            "label": "Exenatide",
            "type": "EXPERIMENTAL",
            "description": "Overweight and obese women were randomized to receive twice daily subcutaneous exenatide injections, titrated to a maximum dose of 10 mcg per injection, for up to 52 weeks. No structured hypocaloric diet or exercise counseling beyond advice to maintain current activity was provided. Participants attended study visits every 2 weeks for the first month and every 4 weeks thereafter.",
            "interventionNames": [
              "Exenatide",
              "Placebo-style injection procedure (twice daily subcutaneous injections without diet counseling)"
            ]
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 1,
          "score": 0.82,
          "status": "matched",
          "ref_item": {
            "label": "Placebo",
            "type": "PLACEBO_COMPARATOR",
            "description": "Subjects will be randomly assigned to the exenatide study treatment group or to the placebo study treatment group. Subjects will have a 33 percent chance of being assigned to the placebo study treatment group and a 66 percent chance of being assigned to exenatide study treatment. Subjects will not be able to choose the study group to which they will be assigned. All study participants will receive individualized dietary counseling based on food logs. Subjects who receive placebo will be assigned to follow a reduced-calorie diet in addition to study treatment. Subjects will not know whether they are receiving exenatide or placebo, but the unblinded members of the study team will know which they are receiving.",
            "interventionNames": [
              "Drug: Placebo",
              "Behavioral: Dietary counseling"
            ]
          },
          "pred_item": {
            "label": "Hypocaloric Diet plus Placebo Injections",
            "type": "ACTIVE_COMPARATOR",
            "description": "Overweight and obese women were randomized to receive matched placebo subcutaneous injections twice daily plus structured hypocaloric diet counseling for up to 52 weeks. The hypocaloric diet targeted approximately a 500 kcal/day reduction from total caloric needs, which were determined from measured resting metabolic rate. Nutrition counseling was provided at every study visit. Participants were instructed to maintain their usual physical activity levels.",
            "interventionNames": [
              "Hypocaloric Diet Counseling",
              "Placebo Injection"
            ]
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.armsInterventionsModule.interventions",
      "algorithm": "hungarian",
      "ref_count": 3,
      "pred_count": 4,
      "similarity_matrix": [
        [
          0.99,
          0.2,
          0.05,
          0.55
        ],
        [
          0.1,
          0.92,
          0.05,
          0.4
        ],
        [
          0.05,
          0.3,
          0.92,
          0.2
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.99,
          "status": "matched",
          "ref_item": {
            "type": "DRUG",
            "name": "Exenatide",
            "description": "Subjects will inject 5mcg of exenatide subcutaneously 15 minutes before the morning and evening meal for the first 2 weeks of the study. At study week 2, subjects will increase to 10mcg twice daily for the remainder of the study.",
            "armGroupLabels": [
              "Exenatide"
            ]
          },
          "pred_item": {
            "type": "DRUG",
            "name": "Exenatide",
            "description": "Twice daily subcutaneous injections of exenatide, titrated to a maximum dose of 10 mcg per injection, administered before meals for up to 52 weeks.",
            "armGroupLabels": [
              "Exenatide"
            ]
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 1,
          "score": 0.92,
          "status": "matched",
          "ref_item": {
            "type": "DRUG",
            "name": "Placebo",
            "description": "Subjects will inject 5mcg of identically dispensed placebo subcutaneously 15 minutes before the morning and evening meal for the first 2 weeks of the study. At study week 2, subjects will increase to 10mcg twice daily for the remainder of the study.",
            "armGroupLabels": [
              "Placebo"
            ]
          },
          "pred_item": {
            "type": "DRUG",
            "name": "Placebo Injection",
            "description": "Matched twice daily subcutaneous placebo injections administered before meals to mimic exenatide administration, used in conjunction with hypocaloric diet counseling.",
            "armGroupLabels": [
              "Hypocaloric Diet plus Placebo Injections"
            ]
          }
        },
        {
          "ref_idx": 2,
          "pred_idx": 2,
          "score": 0.92,
          "status": "matched",
          "ref_item": {
            "type": "BEHAVIORAL",
            "name": "Dietary counseling",
            "description": "All subjects will also receive individualized dietary counseling. Subjects in the placebo group will be counseled to follow a hypocaloric diet.",
            "armGroupLabels": [
              "Placebo"
            ]
          },
          "pred_item": {
            "type": "BEHAVIORAL",
            "name": "Hypocaloric Diet Counseling",
            "description": "Structured nutritional counseling recommending a hypocaloric diet with an approximate 500 kcal/day deficit from measured resting metabolic rateâ€“based caloric needs. Counseling was provided at every study visit; no specific exercise program was prescribed, and participants were instructed to maintain their usual activity.",
            "armGroupLabels": [
              "Hypocaloric Diet plus Placebo Injections"
            ]
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.outcomesModule.primaryOutcomes",
      "algorithm": "hungarian",
      "ref_count": 1,
      "pred_count": 1,
      "similarity_matrix": [
        [
          0.78
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.78,
          "status": "matched",
          "ref_item": {
            "measure": "Change in Body Weight",
            "description": "Change in body weight after 12 weeks of treatment with exenatide or placebo twice daily injections. This outcome compares baseline and 12 week body weight.",
            "timeFrame": "12 weeks"
          },
          "pred_item": {
            "measure": "Change in body weight among early high responders",
            "description": "Long-term change in body weight in women with overweight or obesity who achieved at least 5% weight loss at 12 weeks (high responders) after randomization to exenatide or hypocaloric diet plus placebo injections.",
            "timeFrame": "From baseline through up to 52 weeks of treatment (primary analysis performed at 24 weeks due to funding limitations)"
          }
        }
      ]
    }
  ]
}